Key result
Hemoadsorption therapy during extracorporeal membrane oxygenation is proposed as a promising option to control excessive inflammatory response and preserve organ function.
Why the study?
Does hemoadsorption therapy improve hemodynamic and metabolic stabilization in patients on ECMO with overwhelming inflammatory response?
Does hemoadsorption therapy improve hemodynamic and metabolic stabilization in patients on ECMO with overwhelming inflammatory response?
Hemoadsorption therapy during ECMO may be a promising adjunctive treatment to control excessive inflammatory responses and preserve organ function.
Answers are grounded in this paper and cite their sources.
ECMO-associated cytokine elevation may warrant monitoring in sepsis and post-CPB; leaves open whether targeted anti-inflammatory interventions improve outcomes.
Extracorporeal membrane oxygenation (ECMO) is an increasingly used technology for mechanical support of respiratory and cardio-circulatory failure. Excessive systemic inflammatory response is observed during sepsis and after cardiopulmonary bypass (CPB) with similar clinical features. The overwhelming inflammatory response is characterized by highly elevated pro- and anti-inflammatory cytokine levels. The excessive cytokine release during the overwhelming inflammatory response may result in multiple organ damage and failure. During ECMO therapy activation of complement and contact systems occur which may be followed by cytokine release. Controlling excessively increased cytokines may be considered as a valuable treatment option. Hemoadsorption therapy may be used to decrease cytokine levels in case of excessive inflammatory response and due to its unspecific adsorptive characteristics also substances like myoglobin, free hemoglobin or bilirubin. Controlling pro-inflammatory response with hemoadsorption may have positive impact on the endothelial glycocalix and also may be advantageous for maintenance of the vascular barrier function which plays a pivotal role in the development of tissue edema and oxygen mismatch. Hemoadsorption therapy seems to offer a promising new option for the treatment of patients with overwhelming inflammatory response leading to faster hemodynamic and metabolic stabilization finally resulting in preserved organ functions.
No takes yet. Share an insight, caveat, or question.
Datzmann et al. (2018) conducted a review in Respiratory and cardio-circulatory failure with systemic inflammatory response. Hemoadsorption therapy during ECMO was evaluated. Hemoadsorption therapy during extracorporeal membrane oxygenation is proposed as a promising option to control excessive inflammatory response and preserve organ function.
Synapse has enriched 10 related papers. Consider them for comparative context: